Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 16, 2026

Disney Stock Price Prediction: Where Will The Stock be In 2027?

View original at finance.yahoo.com
“The sell-off was amplified by a 77.07% plunge in operating cash flow to $735 million, driven largely by accelerated tax payments tied to California wildfire disaster relief, reflecting a one-time timing item rather than any change in underlying business performance.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Disney stock rating is BUY with 90% confidence level

    60% confidence

  • Management targeting a 10% SVOD operating margin for the full year FY2026

    60% confidence

  • Disney price target is $116.32 with 15.06% upside from current price of $101.10

    60% confidence

  • Operating cash flow plunge was driven by accelerated tax payments tied to California wildfire disaster relief, reflecting a one-time timing item rather than any change in underlying business performance

    60% confidence

  • 84% of covering analysts rated bullish on Disney

    60% confidence

  • Strong fundamental visibility and broad institutional support justifies 90% confidence level

    60% confidence

  • Management guided for double-digit adjusted EPS growth in both FY2026 and FY2027

    60% confidence

Data points we hold from this source

The Walt Disney Company · stock price101.10 USD
The Walt Disney Company · experiences revenue10 USD
The Walt Disney Company · experiences operating income3.3 USD
The Walt Disney Company · eps1.63 USD
The Walt Disney Company · operating cash flow735 USD
The Walt Disney Company · streaming operating income450 USD
The Walt Disney Company · total streaming subscribers196 millions
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Disney Stock Price Prediction: Where Will The Stock be In 2027? — Source | Via News | Finance Via News